Investigational Drug Details
| Drug ID: | D209 |
| Drug Name: | Lisinopril |
| Synonyms: | |
| Type: | small molecule |
| DrugBank ID: | DB00722 |
| DrugBank Description: | Lisinopril is an angiotensin converting enzyme inhibitor (ACEI) used to treat hypertension, heart failure, and myocardial infarction.[L8384,L8387,L8390] Lisinopril and [captopril] are the only ACEIs that are not prodrugs.[A184853] It functions by inhibition of angiotensin converting enzyme as well as the renin angiotensin aldosterone system.[A184781,A184808,A184817] ACEIs are commonly used as a first line therapy in the treatment of hypertension, along with thiazide diuretics or beta blockers.[A184844] Lisinopril was granted FDA approval on 29 December 1987.[L8384] |
| PubChem ID: | 5362119 |
| CasNo: | 76547-98-3 |
| Repositioning for NAFLD: | Yes |
| SMILES: | NCCCC[C@H](N[C@@H](CCC1=CC=CC=C1)C(O)=O)C(=O)N1CCC[C@H]1C(O)=O |
| Structure: |
|
| InChiKey: | RLAWWYSOJDYHDC-BZSNNMDCSA-N |
| Molecular Weight: | 405.4879 |
| DrugBank Targets: | Angiotensin-converting enzyme; Renin |
| DrugBank MoA: | Angiotensin II constricts coronary blood vessels and is positively inotropic, which under normal circumstances, would increase vascular resistance and oxygen consumption.[A184781] This action can eventually lead to myocyte hypertrophy and vascular smooth muscle cell proliferation.[A184781] Lisinopril is an angiotensin converting enzyme inhibitor (ACEI), preventing the conversion of angiotensin I to angiotensin II.[A184781,A184808] This action prevents myocyte hypertrophy and vascular smooth muscle cell proliferation seen in untreated patients.[A184808] Increased levels of bradykinin also exhibit vasodilating effects for patients taking ACEIs.[A184808] Lisinopril also inhibits renin's conversion of angiotensin to angiotensin I.[A184817] |
| DrugBank Pharmacology: | Lisinopril is an angiotensin converting enzyme inhibitor used to treat hypertension, heart failure, and myocardial infarction.[L8384,L8387,L8390] Lisinopril is not a prodrug, and functions by inhibition of angiotensin converting enzyme as well as the renin angiotensin aldosterone system.[A184781,A184808,A184817] It has a wide therapeutic index and a long duration of action as patients are generally given 10-80mg daily.[L8384,L8387,L8390] |
| DrugBank Indication: | Lisinopril is indicated for the treatment of acute myocardial infarction, hypertension in patients ≥6 years, and as an adjunct therapy for heart failure.[L8384,L8387] A combination product with hydrochlorothiazide is indicated for the treatment of hypertension.[L8390] |
| Targets: | |
| Therapeutic Category: | |
| Clinical Trial Progress: | |
| Latest Progress: |
| Trial ID | Source ID | Phases | Status | Study Results | Start Date | Last Update Posted | |
|---|---|---|---|---|---|---|---|
| L0416 | NCT01738035 | PHASE2 | COMPLETED | NO | 2012-12 | 2015-09-24 | Details |
| L1181 | NCT00667576 | PHASE2 | COMPLETED | YES | 2008-04 | 2012-01-20 | Details |
| Strategy ID | Strategy | Synonyms | Related Targets | Related Drugs |
|---|
| Article ID | PMID | Source | Title |
|---|